· 2021 financing will be a catalyst to further establish Neurelis as a best-in-class epilepsy company
· Funds will enhance growth and commercial penetration of company’s lead orphan drug product, VALTOCO? (diazepam nasal spray), and support pipeline development and expansion
· Company also announces appointment of healthcare industry expert Alexander Kwit to its Board of Directors
Jumpcode Genomics – a genome technology company focused on improving the understanding of human disease – today announced it raised $21 million in a Series B round of funding. The round was co-led by Baird Capital and Arboretum Ventures and included existing investor LYZZ Capital. Jumpcode also announced the appointment of Frank Witney to its Board of Directors, further expanding the company’s leadership team. Additionally, the company announced the move of its headquarters into larger office and laboratory space.
SAN DIEGO, December 3, 2020 – Qpex Biopharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of innovative anti-infective therapies, announced today that it has initiated a Phase 1 clinical study of QPX7728, its novel ultra-broad-spectrum beta-lactamase inhibitor.